Citadel Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $152M | Sell |
339,298
-87,762
| -21% | -$40.9M | 0.02% | 587 |
|
|
2025
Q4 | $194M | Buy |
427,060
+253,558
| +146% | +$109M | 0.03% | 498 |
|
|
2025
Q3 | $68M | Buy |
173,502
+144,675
| +502% | +$60.5M | 0.01% | 1114 |
|
|
2025
Q2 | $12.8M | Buy |
28,827
+23,808
| +474% | +$11M | ﹤0.01% | 2697 |
|
|
2025
Q1 | $2.43M | Sell |
5,019
-157,162
| -97% | -$73.2M | ﹤0.01% | 5150 |
|
|
2024
Q4 | $65.3M | Buy |
162,181
+111,949
| +223% | +$51.9M | 0.01% | 1042 |
|
|
2024
Q3 | $23.4M | Sell |
50,232
-54,363
| -52% | -$26.1M | ﹤0.01% | 1886 |
|
|
2024
Q2 | $49M | Buy |
104,595
+22,622
| +28% | +$9.82M | 0.01% | 1167 |
|
|
2024
Q1 | $34.3M | Sell |
81,973
-244,707
| -75% | -$103M | 0.01% | 1531 |
|
|
2023
Q4 | $133M | Buy |
326,680
+298,936
| +1,077% | +$110M | 0.03% | 528 |
|
|
2023
Q3 | $9.65M | Buy |
27,744
+27,631
| +24,452% | +$9.66M | ﹤0.01% | 2724 |
|
|
2023
Q2 | $39.8K | Sell |
113
-83,693
| -100% | -$28.2M | ﹤0.01% | 12072 |
|
|
2023
Q1 | $26.4M | Sell |
83,806
-119,805
| -59% | -$35.9M | 0.01% | 1649 |
|
|
2022
Q4 | $58.8M | Buy |
203,611
+189,846
| +1,379% | +$57.9M | 0.01% | 997 |
|
|
2022
Q3 | $3.99M | Buy |
+13,765
| New | +$3.96M | ﹤0.01% | 4253 |
|
|
2022
Q2 | – | Sell |
-42,605
| Closed | -$11.4M | – | 14208 |
|
|
2022
Q1 | $11.1M | Sell |
42,605
-209,986
| -83% | -$49.8M | ﹤0.01% | 2788 |
|
|
2021
Q4 | $55.5M | Sell |
252,591
-161,538
| -39% | -$31.4M | 0.01% | 1088 |
|
|
2021
Q3 | $75.1M | Buy |
414,129
+24,539
| +6% | +$4.79M | 0.02% | 836 |
|
|
2021
Q2 | $78.6M | Sell |
389,590
-1,329,590
| -77% | -$278M | 0.02% | 812 |
|
|
2021
Q1 | $369M | Buy |
1,719,180
+240,821
| +16% | +$52.9M | 0.09% | 136 |
|
|
2020
Q4 | $349M | Buy |
1,478,359
+566,347
| +62% | +$130M | 0.09% | 129 |
|
|
2020
Q3 | $248M | Buy |
+912,012
| New | +$252M | 0.07% | 146 |
|
|
2020
Q2 | – | Sell |
-446,956
| Closed | -$121M | – | 10572 |
|
|
2020
Q1 | $106M | Sell |
446,956
-583,879
| -57% | -$134M | 0.05% | 317 |
|
|
2019
Q4 | $226M | Buy |
1,030,835
+316,096
| +44% | +$64M | 0.1% | 149 |
|
|
2019
Q3 | $121M | Buy |
714,739
+573,869
| +407% | +$102M | 0.06% | 318 |
|
|
2019
Q2 | $25.8M | Buy |
140,870
+3,299
| +2% | +$577K | 0.01% | 1195 |
|
|
2019
Q1 | $25.3M | Sell |
137,571
-745,952
| -84% | -$138M | 0.01% | 1141 |
|
|
2018
Q4 | $146M | Buy |
883,523
+54,690
| +7% | +$9.48M | 0.08% | 196 |
|
|
2018
Q3 | $160M | Sell |
828,833
-696,560
| -46% | -$124M | 0.07% | 249 |
|
|
2018
Q2 | $259M | Buy |
1,525,393
+749,719
| +97% | +$116M | 0.13% | 102 |
|
|
2018
Q1 | $126M | Sell |
775,674
-938,586
| -55% | -$153M | 0.07% | 236 |
|
|
2017
Q4 | $257M | Buy |
1,714,260
+366,651
| +27% | +$54.3M | 0.16% | 98 |
|
|
2017
Q3 | $205M | Sell |
1,347,609
-277,444
| -17% | -$41.8M | 0.16% | 90 |
|
|
2017
Q2 | $209M | Buy |
1,625,053
+597,399
| +58% | +$71.9M | 0.18% | 74 |
|
|
2017
Q1 | $112M | Buy |
1,027,654
+993,845
| +2,940% | +$87.5M | 0.1% | 167 |
|
|
2016
Q4 | $2.49M | Buy |
33,809
+31,272
| +1,233% | +$2.54M | ﹤0.01% | 2698 |
|
|
2016
Q3 | $221K | Sell |
2,537
-52,617
| -95% | -$4.97M | ﹤0.01% | 6171 |
|
|
2016
Q2 | $4.74M | Sell |
55,154
-235,088
| -81% | -$20.3M | 0.01% | 1857 |
|
|
2016
Q1 | $23.1M | Sell |
290,242
-418,244
| -59% | -$37.8M | 0.03% | 675 |
|
|
2015
Q4 | $89.1M | Sell |
708,486
-1,640,384
| -70% | -$198M | 0.1% | 209 |
|
|
2015
Q3 | $245M | Buy |
2,348,870
+1,899,809
| +423% | +$244M | 0.23% | 55 |
|
|
2015
Q2 | $55.5M | Buy |
449,061
+7,265
| +2% | +$915K | 0.05% | 460 |
|
|
2015
Q1 | $52.1M | Sell |
441,796
-240,616
| -35% | -$28.8M | 0.05% | 464 |
|
|
2014
Q4 | $81.1M | Buy |
682,412
+561,776
| +466% | +$63.3M | 0.08% | 263 |
|
|
2014
Q3 | $13.5M | Sell |
120,636
-108,163
| -47% | -$10.3M | 0.01% | 1162 |
|
|
2014
Q2 | $21.7M | Buy |
228,799
+171,249
| +298% | +$12M | 0.02% | 758 |
|
|
2014
Q1 | $4.07M | Sell |
57,550
-216,899
| -79% | -$17.2M | ﹤0.01% | 1960 |
|
|
2013
Q4 | $20.4M | Buy |
274,449
+263,062
| +2,310% | +$18.3M | 0.03% | 788 |
|
|
2013
Q3 | $864K | Buy |
+11,387
| New | +$906K | ﹤0.01% | 3253 |
|
Other funds holding VRTX
VCM
VPM
Citadel Advisors's VRTX Position: Q1 2026 in Review
Citadel Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 21% in Q1 2026, selling an estimated $40.9M and leaving 339,298 shares worth $152M. The position accounts for 0.02% of the portfolio, ranked #587.
Citadel Advisors first reported a position in VRTX in Q3 2013 and has held it in 49 quarters since. The position peaked at $369M in Q1 2021. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Citadel Advisors held 339,298 shares of Vertex Pharmaceuticals worth $152M as of Q1 2026.
- Citadel Advisors sold 87,762 Vertex Pharmaceuticals shares in Q1 2026, an estimated $40.9M.
- Vertex Pharmaceuticals made up 0.02% of Citadel Advisors's portfolio in Q1 2026, its #587 holding.
- Citadel Advisors first reported a position in Vertex Pharmaceuticals in Q3 2013 and has held it in 49 quarters since.
- Citadel Advisors's Vertex Pharmaceuticals position peaked at $369M in Q1 2021.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.